Skip to main content

Monte Rosa Therapeutics, Inc.

GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826457

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

Q4 2023 vs. Q3 2023

How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of GLUE: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders71710
Shares42.0M40.1M−1.94M (−4.6%)
Value$201.4M$226.6M+$25.2M (+12.5%)

New holders (13)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to GLUE in Q4 2023
InstitutionSharesValue% of portfolio
Caption Management, LLC90,690$512.4K0.06%
Jane Street Group, LLC70,715$399.5K0.00%
Millennium Management LLC67,279$380.1K0.00%
Sphera Funds Management Ltd.48,511$274.1K0.05%
Susquehanna International Group, LLP46,387$262.1K0.00%
Balyasny Asset Management LLC38,802$219.2K0.00%
Acadian Asset Management LLC28,861$161.0K0.00%
Squarepoint Ops LLC17,462$98.7K0.00%
Cubist Systematic Strategies, LLC10,602$59.9K0.00%
Invesco Ltd.10,518$59.4K0.00%
Point72 Middle East FZE9,290$52.5K0.00%
Comerica Bank841$4.75K0.00%
Advisor Group Holdings, Inc.400$2.26K0.00%

Sold out (13)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.